These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25629523)

  • 1. The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.
    Dicks MD; Guzman E; Spencer AJ; Gilbert SC; Charleston B; Hill AV; Cottingham MG
    Vaccine; 2015 Feb; 33(9):1121-8. PubMed ID: 25629523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
    Warimwe GM; Lorenzo G; Lopez-Gil E; Reyes-Sandoval A; Cottingham MG; Spencer AJ; Collins KA; Dicks MD; Milicic A; Lall A; Furze J; Turner AV; Hill AV; Brun A; Gilbert SC
    Virol J; 2013 Dec; 10():349. PubMed ID: 24304565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.
    Dicks MD; Spencer AJ; Coughlan L; Bauza K; Gilbert SC; Hill AV; Cottingham MG
    Sci Rep; 2015 Nov; 5():16756. PubMed ID: 26576856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
    Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
    J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
    Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
    J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
    Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
    Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses.
    Marquez-Martinez S; Salisch N; Serroyen J; Zahn R; Khan S
    PLoS One; 2024; 19(4):e0299215. PubMed ID: 38626093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.
    Yang P; Li T; Liu N; Gu H; Han L; Zhang P; Li Z; Wang Z; Zhang S; Wang X
    Antiviral Res; 2015 Sep; 121():145-51. PubMed ID: 26112646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.
    Radosevic K; Wieland CW; Rodriguez A; Weverling GJ; Mintardjo R; Gillissen G; Vogels R; Skeiky YA; Hone DM; Sadoff JC; van der Poll T; Havenga M; Goudsmit J
    Infect Immun; 2007 Aug; 75(8):4105-15. PubMed ID: 17526747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.
    Rhee EG; Blattman JN; Kasturi SP; Kelley RP; Kaufman DR; Lynch DM; La Porte A; Simmons NL; Clark SL; Pulendran B; Greenberg PD; Barouch DH
    J Virol; 2011 Jan; 85(1):315-23. PubMed ID: 20962088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
    Fitzgerald JC; Gao GP; Reyes-Sandoval A; Pavlakis GN; Xiang ZQ; Wlazlo AP; Giles-Davis W; Wilson JM; Ertl HC
    J Immunol; 2003 Feb; 170(3):1416-22. PubMed ID: 12538702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
    Radosevic K; Rodriguez A; Lemckert AA; van der Meer M; Gillissen G; Warnar C; von Eyben R; Pau MG; Goudsmit J
    Clin Vaccine Immunol; 2010 Nov; 17(11):1687-94. PubMed ID: 20826614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
    Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
    Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
    Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
    Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimpanzee-origin adenovirus vectors as vaccine carriers.
    Tatsis N; Tesema L; Robinson ER; Giles-Davis W; McCoy K; Gao GP; Wilson JM; Ertl HC
    Gene Ther; 2006 Mar; 13(5):421-9. PubMed ID: 16319951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.
    Medina GN; Montiel N; Diaz-San Segundo F; Sturza D; Ramirez-Medina E; Grubman MJ; de los Santos T
    Clin Vaccine Immunol; 2015 Nov; 23(2):125-36. PubMed ID: 26607309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.
    Pichla-Gollon SL; Lin SW; Hensley SE; Lasaro MO; Herkenhoff-Haut L; Drinker M; Tatsis N; Gao GP; Wilson JM; Ertl HC; Bergelson JM
    J Virol; 2009 Jun; 83(11):5567-73. PubMed ID: 19279092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.